Legal basis of the Advanced Therapies Regulation.
Advanced therapy medicinal products consist of gene therapy, somatic cell therapy and tissue engineered products. Due to their specific manufacturing process and mode of action these products require specially tailored legislation. With Regulation (EC) No. 1394/2007, these needs have been met. Definitions of gene therapy, somatic cell therapy and tissue engineered products were laid down. A new committee, the Committee for Advanced Therapies, was founded, special procedures such as the certification procedure for small- and medium-sized enterprises were established and the technical requirements for Marketing Authorisation Applications (quality, non-clinical and clinical) were revised.
Jekerle
V
V
European Medicines Agency, 7 Westferry Circus, Canary Wharf, E14 4HB, London, UK. veronika.jekerle@emea.europa.eu
Schröder
C
C
Pedone
E
E
D017690:Cell Transplantation / Q000331:legislation & jurisprudence*; D002568:Certification / Q000331:legislation & jurisprudence; D005060:Europe; D015316:Genetic Therapy / Q000331:legislation & jurisprudence*; D005858:Germany; D006801:Humans; D008389:Marketing of Health Services; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D023822:Tissue Engineering / Q000331:legislation & jurisprudence*